Aquilon Pharmaceuticals

Executive Summary

Aquilon Pharmaceuticals is a Belgian PharmaTech spin-off from Liège University, specializing in next-generation formulation technology for inhaled medications. Its core platform enhances lung deposition and local bioavailability of existing and new inhaled drugs, aiming to improve efficacy in respiratory conditions such as asthma, COPD, and nasal disorders. Founded in 2017, the company is privately held and operates as a preclinical-stage drug delivery company with a strong intellectual property base. Aquilon's technology addresses key limitations of conventional inhalation therapies by optimizing particle engineering and delivery mechanisms, potentially enabling better therapeutic outcomes and patient adherence. While the company has not disclosed funding rounds or valuation, its unique approach positions it well in the competitive pulmonary drug delivery landscape. Given its early stage, the primary near-term focus is likely on advancing lead candidates through preclinical validation, securing initial financing, and establishing partnerships with pharmaceutical developers. The company's progress will depend on demonstrating clear in vivo proof-of-concept and differentiation from established inhaled formulation technologies.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Preclinical Proof-of-Concept Data for Lead Inhaled Candidate in COPD Model60% success
• TBDPartnership or Licensing Deal with Mid-Size Pharma for Nasal Delivery Platform40% success